Ondansetron for the Treatment of Methamphetamine Dependence - 1

The purpose of this study is to assess ondansetron for the treatment of methamphetamine dependence.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Amphetamine-Related Disorders Chemically-Induced Disorders Mental Disorders Substance-Related Disorders

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

South Bay Treatment Center, Chula Vista, California, United States

About this study

This study was designed to be a preliminary assessment of the efficacy and safety of 3-wide range doses of ondansetron (0.25, 1.0 and 4.0 mg taken orally twice per day) to reduce methamphetamine use in subjects with methamphetamine dependence and to determine the optimal dose of ondansetron.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

18 years of age. Treatment seeking for meth dependence.

Exclusion criteria

Please contact site director for more details.

Treatment and study plan

ondansetron

Drug

Primary outcomes

Clinicial improvement

Sponsors and collaborators

Lead sponsor

National Institute on Drug Abuse (NIDA)

Nih

Collaborators

University of Texas

Registry information

Official study title

Double-Blind, Placebo-Controlled, Dose Response Trial of Ondansetron for the Treatment of Methamphetamine Dependence.

Important dates

Study start: 2002
Study completion: 2004
First posted: Jun 18, 2002
Registry last updated: Jan 12, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed